Junji Furuse


Ontology type: schema:Person     


Person Info

NAME

Junji

SURNAME

Furuse

Publications in SciGraph latest 50 shown

  • 2022-01-31 Treatments for elderly cancer patients and reforms to social security systems in Japan in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 2022-01-19 The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 in SCIENTIFIC REPORTS
  • 2021-06-18 Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113 in SCIENTIFIC REPORTS
  • 2021-02-23 Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms in EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
  • 2021-01-03 Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study in JOURNAL OF GASTROENTEROLOGY
  • 2021-01-02 FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2020-12-30 Correction to: Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) in JOURNAL OF GASTROENTEROLOGY
  • 2020-10-26 Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study) in JOURNAL OF GASTROENTEROLOGY
  • 2020-10-05 Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies in NATURE MEDICINE
  • 2020-10-01 Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study in BMC CANCER
  • 2020-09-03 Patterns of Recurrence and Its Effective Treatment in DISEASES OF THE GALLBLADDER
  • 2020-06-13 Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study) in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 2020-03-20 First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2020-02-27 Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial in JOURNAL OF GASTROENTEROLOGY
  • 2020-01-29 Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelines in JOURNAL OF GASTROENTEROLOGY
  • 2019-05-03 Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL) in MEDICAL ONCOLOGY
  • 2019-04-30 A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies in INVESTIGATIONAL NEW DRUGS
  • 2019-03-12 Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately in ANNALS OF SURGICAL ONCOLOGY
  • 2018-12-04 First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2018-10-19 Clinical characteristics of Japanese patients with epithelioid hemangioendothelioma: a multicenter retrospective study in BMC CANCER
  • 2018-09-10 Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients in INVESTIGATIONAL NEW DRUGS
  • 2018-07-10 An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018-04-28 Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 2018-04-09 A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018-03-27 Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report in SURGICAL CASE REPORTS
  • 2018-03-10 APC:T1556fs and STK11 mutations in duodenal adenomas and adenocarcinomas in SURGERY TODAY
  • 2017-06-20 A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2017-05-04 Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data in BRITISH JOURNAL OF CANCER
  • 2017-02-16 Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer in JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
  • 2017-02-12 A pathological complete response after combined chemotherapy of gemcitabine and S-1 in advanced biliary tract cancer with para-aortic lymph nodes metastasis: a case report in SURGICAL CASE REPORTS
  • 2017-01-12 Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer in BRITISH JOURNAL OF CANCER
  • 2016-08-22 Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial in JOURNAL OF GASTROENTEROLOGY
  • 2016-04-22 Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON in JOURNAL OF GASTROENTEROLOGY
  • 2016-03-01 Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study in JOURNAL OF GASTROENTEROLOGY
  • 2016-02-03 Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-08-12 A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2014-12-30 Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2014-12-13 Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer in INVESTIGATIONAL NEW DRUGS
  • 2013-09-03 Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics in INVESTIGATIONAL NEW DRUGS
  • 2013-06-29 A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2013-04-16 Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer in BRITISH JOURNAL OF CANCER
  • 2013-04-04 Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics in INVESTIGATIONAL NEW DRUGS
  • 2013-03-24 A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2012-08 Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system. in CLINICAL DRUG INVESTIGATION
  • 2012-08 Current Status of Hepatocellular Carcinoma Treatment in Japan in CLINICAL DRUG INVESTIGATION
  • 2011-11-26 Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2010-11-10 Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma in BMC CANCER
  • 2010-08 Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients in CLINICAL PHARMACOKINETICS
  • 2010-07-13 Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan in BRITISH JOURNAL OF CANCER
  • 2009-12-05 A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.411205.3", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417323.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.459686.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.484107.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.415797.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.486756.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.268441.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410807.a", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418490.0", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.482763.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.136304.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410818.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.420115.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410797.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.265008.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414944.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418599.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416629.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.497282.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417755.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.177174.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.470350.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.415740.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.21107.35", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416859.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.258799.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.414280.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.272242.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410800.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.258622.9", 
            "type": "Organization"
          }
        ], 
        "familyName": "Furuse", 
        "givenName": "Junji", 
        "id": "sg:person.01154650450.78", 
        "identifier": [
          {
            "name": "orcid_id", 
            "type": "PropertyValue", 
            "value": "0000-0003-0663-6117"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154650450.78", 
          "https://orcid.org/0000-0003-0663-6117"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-05-20T08:04", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/person/person_678.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01154650450.78'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01154650450.78'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01154650450.78'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01154650450.78'


     

    This table displays all metadata directly associated to this object as RDF triples.

    79 TRIPLES      11 PREDICATES      42 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.01154650450.78 schema:affiliation Nf5918603df654bfda0aa03092c1335ea
    2 grid-institutes:grid.136304.3
    3 grid-institutes:grid.177174.3
    4 grid-institutes:grid.21107.35
    5 grid-institutes:grid.258622.9
    6 grid-institutes:grid.258799.8
    7 grid-institutes:grid.265008.9
    8 grid-institutes:grid.268441.d
    9 grid-institutes:grid.272242.3
    10 grid-institutes:grid.410797.c
    11 grid-institutes:grid.410800.d
    12 grid-institutes:grid.410807.a
    13 grid-institutes:grid.410818.4
    14 grid-institutes:grid.414280.b
    15 grid-institutes:grid.414944.8
    16 grid-institutes:grid.415740.3
    17 grid-institutes:grid.415797.9
    18 grid-institutes:grid.416629.e
    19 grid-institutes:grid.416859.7
    20 grid-institutes:grid.417323.0
    21 grid-institutes:grid.417755.5
    22 grid-institutes:grid.418490.0
    23 grid-institutes:grid.418599.8
    24 grid-institutes:grid.420115.3
    25 grid-institutes:grid.459686.0
    26 grid-institutes:grid.470350.5
    27 grid-institutes:grid.482763.c
    28 grid-institutes:grid.484107.e
    29 grid-institutes:grid.486756.e
    30 grid-institutes:grid.497282.2
    31 schema:familyName Furuse
    32 schema:givenName Junji
    33 schema:identifier N202b41eb0b444fa8be085641136d77c9
    34 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154650450.78
    35 https://orcid.org/0000-0003-0663-6117
    36 schema:sdDatePublished 2022-05-20T08:04
    37 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    38 schema:sdPublisher N4de23e15800845a2a302e902db767b3d
    39 sgo:license sg:explorer/license/
    40 sgo:sdDataset persons
    41 rdf:type schema:Person
    42 N202b41eb0b444fa8be085641136d77c9 schema:name orcid_id
    43 schema:value 0000-0003-0663-6117
    44 rdf:type schema:PropertyValue
    45 N4de23e15800845a2a302e902db767b3d schema:name Springer Nature - SN SciGraph project
    46 rdf:type schema:Organization
    47 Nf5918603df654bfda0aa03092c1335ea schema:affiliation grid-institutes:grid.411205.3
    48 sgo:isCurrent true
    49 rdf:type schema:OrganizationRole
    50 grid-institutes:grid.136304.3 schema:Organization
    51 grid-institutes:grid.177174.3 schema:Organization
    52 grid-institutes:grid.21107.35 schema:Organization
    53 grid-institutes:grid.258622.9 schema:Organization
    54 grid-institutes:grid.258799.8 schema:Organization
    55 grid-institutes:grid.265008.9 schema:Organization
    56 grid-institutes:grid.268441.d schema:Organization
    57 grid-institutes:grid.272242.3 schema:Organization
    58 grid-institutes:grid.410797.c schema:Organization
    59 grid-institutes:grid.410800.d schema:Organization
    60 grid-institutes:grid.410807.a schema:Organization
    61 grid-institutes:grid.410818.4 schema:Organization
    62 grid-institutes:grid.411205.3 schema:Organization
    63 grid-institutes:grid.414280.b schema:Organization
    64 grid-institutes:grid.414944.8 schema:Organization
    65 grid-institutes:grid.415740.3 schema:Organization
    66 grid-institutes:grid.415797.9 schema:Organization
    67 grid-institutes:grid.416629.e schema:Organization
    68 grid-institutes:grid.416859.7 schema:Organization
    69 grid-institutes:grid.417323.0 schema:Organization
    70 grid-institutes:grid.417755.5 schema:Organization
    71 grid-institutes:grid.418490.0 schema:Organization
    72 grid-institutes:grid.418599.8 schema:Organization
    73 grid-institutes:grid.420115.3 schema:Organization
    74 grid-institutes:grid.459686.0 schema:Organization
    75 grid-institutes:grid.470350.5 schema:Organization
    76 grid-institutes:grid.482763.c schema:Organization
    77 grid-institutes:grid.484107.e schema:Organization
    78 grid-institutes:grid.486756.e schema:Organization
    79 grid-institutes:grid.497282.2 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...